CRISPR-Cas9 Editing of Myeloid Lectins Reveals Target-Dependent Transcriptional Remodeling in Tumor-Associated Macrophages

Inside the body's battlefields, tumors do not just grow; they build a fortress. They recruit ordinary immune cells, turning them into allies that protect the cancer rather than destroy it. Among these recruited soldiers are macrophages, large white blood cells that normally patrol tissues to eat up debris and fight infection. But when they enter a tumor, they often change their nature, becoming "tumor-associated macrophages" that help the cancer hide from the immune system, grow new blood vessels, and spread. Scientists have long suspected that these cells are not simply switched on or off by a single signal. Instead, they are constantly reading a complex language of chemical tags on the surface of cancer cells. One part of this language involves sugars, or glycans, which coat the surface of cells like a unique ID card. Specialized receptors on immune cells, known as lectins, act as the readers of these sugar ID cards. When a lectin grabs onto a specific sugar pattern on a tumor, it sends a message into the immune cell, telling it how to behave. The big question has been: which of these sugar-reading receptors are the most important for turning a healthy immune cell into a cancer helper, and what happens inside the cell when that connection is broken?

To answer this, a team of researchers set out to test five specific lectin receptors that they believed might be key players in this process. They chose to work with human cells to ensure the results would be relevant to people, but working with these cells is notoriously difficult. The researchers needed a way to temporarily disable each of the five receptors in living human immune cells to see what changed. They used a precise molecular tool called CRISPR-Cas9, which acts like a pair of molecular scissors to cut specific genes. Instead of using viruses to deliver these scissors, which can be risky, they packaged the scissors and their targeting guides into a protein complex and shot them directly into the cells using a gentle electrical pulse. This method allowed them to edit the cells without leaving behind viral baggage. They first tested their method on a standard laboratory cell line to find the best "scissors" for each job, then moved to fresh human immune cells taken from healthy donors. Once they successfully disabled the receptors, they mixed these edited cells with breast cancer cells in a three-dimensional model that mimics the crowded environment of a real tumor. After letting them interact for a week, they isolated the immune cells that had settled into the tumor environment and read their genetic instructions to see how their behavior had changed.

The results revealed that the immune cells were not simply flipping a switch from "good" to "bad" or vice versa. Instead, breaking the connection with any of the five sugar-reading receptors caused the cells to reorganize their internal energy systems in surprising ways. The researchers found that when these receptors were disabled, the cells consistently changed how they managed their fuel. They shifted their metabolism, altering how they processed fats and sugars to generate energy. This metabolic shift was not random; it was a coordinated response that happened across all the different receptors they tested, suggesting that these sugar readers are deeply tied to the cell's energy management. However, the specific changes depended on which receptor was removed. For instance, disabling one receptor called CLEC6A reduced the cell's drive to build new blood vessels and lowered signals associated with low oxygen, which are common features of a tumor-supporting environment. Disabling another, CD209, had a similar effect on blood vessel growth but also changed how the cell handled lipids.

Perhaps the most striking finding was that the strength of the genetic editing did not always predict the strength of the biological change. One receptor, CLEC4E, was very difficult to disable; the researchers could only break the gene in about one-fifth of the cells. Yet, even with this low success rate, the cells that were successfully edited showed a massive overhaul of their internal programs, particularly in how they managed stress and processed fats. This suggests that even a small number of cells losing this specific receptor can trigger a powerful shift in their behavior. In contrast, another receptor, SELL, was very easy to disable, with the gene broken in most cells, but the resulting changes in the cell's behavior were much more limited. This tells us that the importance of a receptor is not just about how easily it can be turned off, but about how critical it is for the cell's overall function.

The study also clarified what these cells are not doing. The researchers had wondered if removing these sugar readers would simply turn the immune cells into aggressive, inflammation-fighting machines. The data showed this was not the case. Instead of a uniform switch to a "fighting" mode, the cells adopted a complex, mixed state that was specific to which receptor was missing. They did not become standard inflammatory cells; they became cells with a distinct metabolic identity. This challenges the old idea that immune cells in tumors are just stuck in a single "bad" mode that can be fixed by a single switch. Instead, they are in a dynamic state, constantly adjusting their energy use and signaling based on the sugar signals they receive from the tumor.

By mapping these changes, the researchers identified which receptors are the most promising targets for future therapies. They found that CLEC6A and CLEC4E were particularly influential, with their removal leading to the most significant changes in the cell's behavior, even if CLEC4E was hard to edit. This suggests that these two receptors might be the most critical for maintaining the tumor-supporting state. The work also confirmed that the receptors CD209 and SIGLEC9 play a role in sensing the tumor's sugar coat, and disrupting them changes the cell's metabolism and reduces its ability to support tumor growth. The study did not test whether these changes would stop a tumor from growing in a living person, but it provided a clear, detailed map of how these sugar-reading receptors control the internal life of the immune cells that surround cancer. It shows that to change the behavior of the immune system in a tumor, we may need to look beyond simple activation or suppression and instead focus on how these cells manage their energy and respond to the sugar language of the tumor environment.